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Objectives. We sought o validate the safety of transesophageal 
echocardiographically guided early cardioversion i conjunction 
with short-term anticoagulation as a strategy for guiding early 
cardioversion i hospitalized patients with atrial fibrillation. 
Background. Because atrial thrombi are poorly seen by conven- 
tional imaging techniques, everal weeks of prophylactic antico- 
agulation is routinely prescribed before cardioversion. Trans- 
esophageal echocardiography is a superior test for identifying 
atrial thrombi; preliminary feasibility studies have supported its 
use to guide early cardioversion for patients in whom no throm- 
bus is observed, but safety has not been validated in any large 
series. 
Methods. All patients admitted to hospital with atrial fibrilla- 
tion during a 4.5-year period were screened. The inclusion crite- 
rion was a clinical duration of atrial fibrillation >2 days or of 
unknown duration. Patients received anticoagulation with hepa- 
rin/warfarin and underwent conventional transthoracic e hocar- 
diography followed by transesophageal study. Patients in whom 
transesophageal echocardiography revealed no atrial thrombus 
underwent pharmacologic orelectrical cardioversion followed by 
warfarin therapy for 1 month. Cardioversion was deferred in 
patients with evidence of atrial thrombi, and they received pro- 
longed warfarin treatment. 
Results. Two hundred thirty-three patients (86% of those 
eligible) agreed to participate, and 230 underwent transesopha- 
geal echocardiography. Transesophageal chocardiography iden- 
tified 40 atrial thrombi (left atrium 34, right atrium 6) in 34 
patients (15%). One hundred eighty-six (95%) of 196 patients 
without hrombi had successful cardioversion tosinus rhythm, all 
without prolonged anticoagulation, and none (0%, 95% confidence 
interval 0% to 1.6%) experienced a clinical thromboembolic event. 
Eighteen patients with atrial thrombi underwent uneventful car- 
dioversion after prolonged anticoagulation. 
Conclusions. Compared with smaller series that have shown 
only feasibility, this large prospective and consecutive study of 
patients undergoing transesophageal chocardiographically facil- 
itated early cardioversion i conjunction with short-term antico- 
agnlation validates the safety of this strategy. This treatment 
algorithm has a safety profile similar to conventional therapy and 
minimizes both the period of anticoagulation and the overall 
duration of atrial fibrillation. 
(J Am Coil Cardiol 1995;25:1354- 61) 
Thromboembolism as a consequence of atrial fibrillation is a 
major cause of morbidity and mortality. Cardioversion from 
atrial fibrillation is commonly used both to prevent thrombo- 
embolism (1) and to improve left ventricular function (2-5). 
However, up to 7% of patients undergoing cardioversion 
without anticoagulation experience clinical thromboembolism 
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(6-9), presumably as a result of dislodgment of an atrial 
thrombus after resumption of atrial systolic activity. Several 
weeks of warfarin therapy before cardioversion has been 
shown to reduce the incidence of cardioversion-associated 
thromboembolism by 0% to 1.6% (8-10). This recognized 
benefit of prophylactic anticoagulation before cardioversion 
has led to its adoption as the current standard of care for 
patients with atrial fibrillation of >2 days in duration (11,12), 
although no large randomized trials have been reported. 
However, the use of several weeks of anticoagulation is associated 
with significant adverse ffects, most notably an increased risk of 
hemorrhage (8,13). This treatment strategy also results in a 
1-month delay in cardioversion for the great majority of patients 
who would not experience thromboembolism. 
Until the development of two-dimensional transthoracic 
echocardiography, identification of intracardiac thrombi was 
rarely possible except at cardiac surgery or autopsy. Although 
conventional transthoracic echocardiography may identify 
thrombi n the body of the atria, it poorly visualizes the left 
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atrial appendage, the site of most thrombi n patients with 
atrial fibrillation (14,15). A superior test for atrial thrombi 
would obviate the need for several weeks of precardioversion 
anticoagulation i  patients found to be free of thrombus, 
thereby abbreviating the total duration of anticoagulation, 
allowing earlier eturn of sinus rhythm and atrial mechanical 
function (16) and eliminating the need for a second hospital 
admission for cardioversion. 
Because of its excellent visualization of posterior cardiac 
structures, transesophageal chocardiography as rapidly be- 
come the procedure of choice for the detection of left atrial 
pathology, including left atrial tumor, atrial septal defect, 
patent foramen ovale and left atrial thrombus (17-19). The 
procedure has proved well tolerated and safe in both young 
adult and elderly patients (20,21). We and others (22-25) have 
been investigating the use of transesophageal chocardiogra- 
phy as a tool to facilitate cardioversion i  patients with atrial 
fibrillation. These preliminary studies (22-25) have demon- 
strated the feasibility of the transesophageal echocardio- 
graphic approach, but the small number of patients in each 
series has limited validation of its safety. We report he results 
of a large, prospective study of a consecutive group of patients 
over a 4.5-year period who participated in a transesophageal 
echocardiographic guided strategy for early cardioversion, 
which now validates the safety of this approach. 
Methods 
Study patients. We screened 1,299 consecutive adult pa- 
tients admitted (or referred to the echocardiography labora- 
tory) to the Beth Israel Hospital from January 1, 1990 through 
July 31, 1994 or to the University of Connecticut Health 
Center from January 1, 1991 through July 31, 1994 with a 
diagnosis that included atrial fibrillation. Patients were ex- 
cluded if they were receiving long-term anticoagulation with 
warfarin (and had maintained a therapeutic prothrombin time 
-> 15 s), if their clinically estimated duration of atrial fibrillation 
was <2 days, if they spontaneously reverted to sinus rhythm 
before we obtained informed consent, if cardioversion was not 
indicated or desired or if transesophageal chocardiography 
was contraindicated ( sophageal stricture, n = 1) (26). Patients 
with previous or acute thromboembolic events were not ex- 
cluded. Of the 270 patients who qualified, 37 declined to 
participate, 23 at their primary physician's request. The 233 
patients who agreed to participate include 94 described in a 
preliminary report (22). 
Study protocol (Fig. 1). After obtaining written informed 
consent, we began therapeutic heparin anticoagulation i  211 
patients (91%) using an intravenous heparin bolus (3,000 to 
5,000 U) and continuous heparin infusion to maintain apartial 
thromboplastin time of 1.4 to 1.9 times baseline. Twenty-two 
patients were believed (decision of their primary physicians) 
not to be candidates for short-term heparin therapy because of 
recent or previous gastrointestinal bleeding (n = 13), advanced 
age (n = 7) or hemorrhagic stroke (n = 2). So as not to delay 
hospital discharge we also initiated warfarin in 163 patients 
(70%) considered suitablc by their primary physicians for 
postcardioversion a ticoagulation, with a target prothrombin 
time of 1.4 to 1.6 times baseline. 
Conventional transthoracic examination was initially per- 
formed in all subjects. Two-dimensional imaging and Doppler 
transthoracicstudies were obtained using an HP Sonos 500, 
1000 or 1500 (Hewlett-Packard Co.) combined imaging/ 
Doppler echocardiograph equipped with a 2.0-, 2.5- or 
3.5-MHz phased-array transducer. M-mode left atrial dimen- 
sion was measured in the parasternal long-axis view (27). The 
extent of mitral regurgitation was assessed by pulsed and color 
Doppler and graded as 0 (none) to 3 (severe) (28). Left 
ventricular systolic function was defined as abnormal if there 
was evidence of global or regional hypokinesis. 
If no definite thrombus was seen on transthoracic study, 
transesophageal chocardiography was performed within 48 h 
after at least a 6-h fast. Patients received pharyngeal nesthesia 
with 10% lidocaine or Cetacaine spray (Cetylite Industries, 
Inc.) and mild sedation with intravenous meperidine, midazo- 
lam, fentanyl or morphine sulfate, as necessary. Prophylactic 
antibiotics were administered topatients with substantial val- 
vular abnormalities (29). Transesophageal chocardiography 
was attempted using a commercial 5.0-MHz single-plane (n = 
50), biplane (n = 95) or multiplane probe (n = 88). The left 
atrial appendage was initially viewed in the horizontal (0 °) 
plane with the tip of the probe slightly flexed and with the 
probe gently withdrawn until the bifurcation of the pulmonary 
artery was identified. Initial imaging of the left atrial append- 
age in the vertical (90 ° ) plane was followed by posterior and 
anterior otation of the probe until the coronary sinus and 
aorta were visualized, respectively. Multiplane imaging was 
accomplished at 0 ° and 90 ° as described earlier, followed by 
imaging of the left atrial appendage in the horizontal (0 °) plane 
and rotation of the imaging sector from 0 ° to 180 ° during 
continuous visualization of the appendage. An atrial thrombus 
was defined as a well circumscribed and uniformly consistent 
echo-reflective mass of different exture than the atrial wall 
(30). Spontaneous echo contrast, a marker of blood stasis, was 
considered present when dynamic "smokelike" echoes were 
detected within the atria (31). Imaging and Doppler data were 
recorded on videotape for consensus review by at least two 
experienced observers. 
If no atrial thrombi were seen, cardioversion was attempted 
chemically in patients who had received heparin anticoagula- 
tion using either quinidine, procainamide, disopyramide, fie- 
cainide or amiodarone (choice of their primary physician). If 
sinus rhythm was not achieved within 12 to 36 h, direct cur- 
rent cardioversion was performed (three patients refused 
electrical cardioversion after unsuccessful chemical cardiover- 
sion). Heparin was continued for at least 24 h after cardiover- 
sion in those who had received no warfarin, and until the 
prothrombin time was therapeutic for those who had received 
warfarin. Warfarin was continued for 1 month after cardiover- 
sion. 
Because of the concern regarding thrombus development 
during the interval between transesophageal chocardiography 
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Figure 1. Schematic of the transesophageal 
echocardiographic protocol. AF = atrial 
fibrillation; CV = cardioversion; LA = left 
atrial; LAA - left atrial appendage; PTI" = 
partial thromboplastin time; RA = righl 
atrial. 
and cardioversion, patients who did not receive heparin anti- 
coagulation underwent electrical cardioversion immediately 
after transesophageal echocardiography. 
Patients in whom an atrial thrombus was identified received 
>3 weeks of warfarin therapy with a target prothrombin time 
of 1.5 to 1.8 times baseline. Repeat transesophageal chocar- 
diography was then recommended, with cardioversion if no 
thrombus was visualized on the follow-up study. 
All patients were followed up daily during their hospital 
stay and by office visit or telephone call at 3 to 4 weeks after 
cardioversion. No patient was lost to follow-up. The study was 
approved by the Institutional Review Boards of both hospitals, 
and informed consent was obtained from all participants. 
Statistical analysis. Results are expressed as mean value ± 
1 SD. Categoric variables between groups were compared 
using the Fisher exact test, and continuous variables were 
compared using analysis of variance. Severity of mitral regur- 
gitation was analyzed both as a continuous variable (0 to 3) and 
as a dichotomous variable (less than moderate or moderate to 
severe) (StatView II, Abacus Concepts). In all cases a two. 
tailed test was performed, with p <- 0.05 considered significant. 
Confidence intervals for the percent of patients who might 
experience an embolic event after a negative transesophageal 
echocardiogram were calculated using the method of Hanley 
and Lippman-Hand (32). 
Results  
The 233 patients who agreed to participate included 105 
men and 128 women (mean [_+SD] age 73 _+ 13 years, range 30 
to 98). The underlying disorder predisposing to atrial fibrilla- 
tion included one or more of the following: hypertension ( =: 
116 [50%]), ischemic heart disease (n = 56 [24%]), rheumatic 
mitral valve disease (n = 17 [8%]), alcoholism (n = 10 [4%]), 
pneumonia (n = 4 [2%]) and pulmonary embolism (n = 12 
[1%]). In 59 patients (25%) no predisposing condition could be 
identified. The clinically estimated uration of atrial fibrilla- 
tion was 3.4 +_ 6.0 weeks, with a distribution as shown in Figure 
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Figure 2. Histogram depicting duration of atrial fibrillation before 
admission to hospital for the 233 study participants. 
2. The duration of atrial fibrillation was clinically indetermi- 
nate in 48 patients (21% of the total). Thirty-five patients 
(15%) had a history of recent or distant clinical thromboem- 
bolism. Echocardiography. 
Echocardiography. Two hundred thirty-three subjects un- 
derwent ransthoracic echocardiography, followed by uncom- 
plicated transesophageal echocardiography in 230. Trans- 
esophageal echocardiography could not be performed in three 
patients (1.3%) because of inability to intubate the esophagus 
(subsequent results of barium swallows were all normal). 
These patients were treated with conservative therapy (3 weeks 
of warfarin before cardioversion), and their data were not 
included in the subsequent analysis. Transesophageal echocar- 
diographic study and well defined left atrial and left atrial 
appendage borders were identified in all remaining subjects. 
The right atrial appendage was not adequately seen in three 
subjects (1.3%), all of whom had imaging with single-plane 
transesophageal probes. 
Five atrial thrombi were suspected by transthoracic echo- 
cardiography (one right, four left). Of these only two left atrial 
thrombi were confirmed at transesophageal study (sensitivity 
of transthoracic echocardiography for left atrial thrombi 6%; 
specificity 99%; positive predictive value 50%; negative pre- 
dictive value 86%). 
Forty atrial thrombi (34 left atrium, 6 right atrium) were 
identified by transesophageal chocardiography in 34 patients 
(15% of the total group). Ninety-five percent of thrombi were 
visualized only by transesophageal echocardiographic study. 
Thrombus ize varied from 2 to 20 rnm (maximal length). All 
six right atrial thrombi and all but one left atrial thrombus were 
confined to or extended into their respective appendages. Two 
left atrial thrombi (7% of left atrial thrombi) and one right 
atrial thrombus (25% of right atrial thrombi) detected uring 
biplane or multiplane transesophageal chocardiography were 
not visualized in the horizontal (0 °) orientation, but all thrombi 
were identified in the vertical (90 ° ) plane. Spontaneous left 
atrial contrast was identified by transesophageal chocardiog- 
raphy in 49% of the study participants. 
Table 1. Characteristics and Transesophageal Echocardiographic 
Data for 230 Study Patients 
Left Atrial Left Atrial 
Thrombus Thrombus 
Present Absent p 
(n = 34) (n = 196) Value 
Gender (female) 62% 53% 0.45 
Age (yr) 75 _+ 12 72 _+ 13 0.30 
Duration of atrial 2.8 _+ 3.1" 3.5 _+ 6.5? 0.61 
fibrillation (wk) 
Recent thromboembolism 8 (24%) 15 (8%) 0.01 
Left atrial dimension (cm) 4.8 z 0.6 4.5 - 0.8 0.065 
Abnormal left ventricular 61% 32% 0.014 
systolic function 
Left atrial spontaneous 27 (79%) 85 (43%) 0.0002 
contrast 
Severity of mitral 1.2 _+ 0.7 1.4 -- 0.7 0.29 
regurgitation (0-3 +) 
At least moderate mitral 9 (26%) 56 (27%) 0.88 
regurgitation 
*Unknown,  7. ?Unknown,  - 40. Data presented are mean value +_ SD 
or number (%) or percent of patients. 
Echocardiographic indexes associated with left atrial 
thrombi. Left atrial thrombi were significantly more frequent 
among patients with rheumatic mitral valve disease (24%, p = 
0.019) and those with abnormal left ventricular systolic func- 
tion, recent hromboembolism and spontaneous left atrial echo 
contrast (Table 1). However none of these variables was a 
reliable predictor of thrombus for an individual patient be- 
cause of substantial overlap between groups. Patient age, 
gender, duration of atrial fibrillation and left atrial dimension 
(p = 0.065) were not significantly different between groups 
with and without left atrial thrombi (Table 1). Eighty percent 
of study patients had at least mild mitral regurgitation; there 
was no difference in the severity of mitral regurgitation be- 
tween the groups with and without left atrial thrombi (p = 
0.29). Twenty-seven percent of patients had at least moderate 
mitral regurgitation. Analysis of mitral regurgitation as a 
dichotomous variable based on less than or at least moderate 
mitral regurgitation also did not demonstrate a difference 
between the groups with and without atrial thrombi (p = 0.87). 
Transesophageal echocardiography identified spontaneous 
echo contrast within the right atrium in 10% of patients (n = 
24), including five of six patients with right atrial thrombi (vs. 
9% of patients without thrombi, p = 0.001). 
Cardioversion. Cardioversion was deferred in all 34 pa- 
tients with evidence of left or right atrial thrombi. Subse- 
quently three patients with left atrial thrombi died suddenly. 
One experienced a clinical embolic event before death, and a 
second patient was found to be asystolic 5 days after trans- 
esophageal echocardiographic identification of a left atrial 
thrombus (22). A limited autopsy (thorax only) in this latter 
patient found no residual left atrial thrombus. Another patient 
who presented with new atrial fibrillation and acute thrombo- 
embolism to the left leg (confirmed at thrombectomy) had a 
left atrial appendage thrombus identified on transesophageal 
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examination and died 4 days later of overwhelming sepsis. The 
family refused permission for an autopsy. 
Eighteen (58%) of 31 surviving patients have undergone 
uneventful cardioversion after prolonged anticoagulation. 
Thirteen patients unde~ent cardioversion after repeat rans- 
esophageal echocardiography documented no residual throm- 
bi; three patients had cardioversion after 4 weeks of oral 
anticoagulant therapy without repeat transesophageal chocar- 
diography (decision of their prima O, physician), and two 
patients converted spontaneously and uneventfully 1 and 
3 weeks after identification of a left atrial appendage thrombus 
on transesophageal study. 
Of the 13 patients with thrombi who remained in atrial 
fibrillation, one underwent transesophageal chocardiography 
after 4 weeks of anticoagulation, which demonstrated a persis- 
tent 3-ram thrombus in the distal left atrial appendage. Car- 
dioversion has been deferred indefinitely and she continues to 
receive anticoagulation. Repeat ransesophageal chocardiog- 
raphy has been recommended for the remaining patients but 
12 remain in atrial fibrillation and have not had a repeat study. 
Their primary, physicians believed that these patients were not 
optimal candidates for cardioversion. 
In 196 patients (85% of the total) no atrial thrombus was 
visualized by transesophageal chocardiography. Of these pa- 
tients 186 (95%) had successful cardioversion to sinus rhythm; 
none received chronic anticoagulation a d none (0%, 95% 
confidence interval ()~; to 1.65~:) experienced a clinical embolic 
event. One hundred patients (54%) had chemical cardiover- 
sion with either quinidine, procainamide, disopyramide, fie- 
cainide, amiodarone or sotalol. Three patients pontaneously 
converted including two who converted uring transesopha- 
geal echocardiographic examination. The remaining 86 pa- 
tients underwent successful electrical cardioversion either im- 
mediately after transesophageal chocardiography (n = 21) or 
after unsuccessful chemical cardioversion (n = 65). Ten pa- 
tients failed to convert after attempted chemical or electrical 
cardioversion, or both, and continued to receive oral warfarin. 
Discuss ion  
Compared with smaller series (22-25), which showed only 
feasibility, this large prospective and consecutive study of 230 
patients undergoing transesophageal chocardiographically fa- 
cilitated early cardioversion in conjunction with short-term 
anticoagulation validates the safety of this treatment s rategy 
for hospitalized patients with atrial fibrillation. Using the 
treatment algorithm described in Figure 1, with enrollment of 
almost 90% of all eligible patients admitted to our institutions 
over the past 4.5 years, we showed that the safety profile of this 
approach is equal to that of conventional therapy. 
Advantages of early cardioversion from atrial fibrillation. 
Early and safe cardioversion i  concert with short-term anti- 
coagulation and guided by transesophageal echocardiography 
has several advantages over traditional strategies. Currently up 
to 4 weeks of oral anticoagulation is recommended before and 
after cardioversion (11,12), which exposes patients to a signif- 
icant additional risk of a hemorrhagic complication by dou- 
bling their exposure to systemic anticoagulation. The incidence 
of major bleeding appears to be directly related to the length 
as well as the level of anticoagulation a d is exceedingly rare 
in patients who have received oral anticoagulation for <1 
month (8). 
Early cardioversion also offers physiologic advantages over 
traditional therapy. The duration of atrial fibrillation is the 
strongest predictor of who will remain in sinus rhythm after 
cardioversion (33,34). Almost 60% of patients hospitalized foi 
atrial fibrillation have been in atrial fibrillation <1 month (Fig. 
2). Traditional treatment with 3 to 4 weeks of anticoagulation 
before cardioversion more than doubles the total period ot 
atrial fibrillation. The time required for return of atrial me- 
chanical function has been shown to be directly related to the 
duration of atrial fibrillation before cardioversion (16). Pa- 
tients with atrial fibrillation <2 weeks in duration have com- 
plete return of atrial mechanical function within 24 h of 
cardioversion; those with atrial fibrillation <6 weeks in dura- 
tion demonstrate r turn of atrial mechanical function within 
1 week. Patients with atrial fibrillation for longer periods (>6 
weeks) may require up to 3 weeks for return of atrial mechan- 
ical function, Finally, 4 weeks of anticoagulation a d delayed 
cardioversion are often followed by a costly second hospital 
stay. 
Eehocardiographic indexes associated with left atrial 
thrombi. We found a significant increase in the incidence of 
both spontaneous echo contrast and abnormal left ventricular 
systolic function in patients with left atrial thrombi. Spontane- 
ous echo contrast was also identified in nearly half of the 
patients in the series. Although its etiology remains controver- 
sial (35), the strong association between spontaneous echo 
contrast and atrial thrombus (36) suggests that efforts to 
identify atrial thrombus using transesophageal chocardiogra- 
phy should be especially diligent when spontaneous echo 
contrast isobserved. Left ventricular dysfunction has also been 
associated with an increased risk of thromboembolism (37). 
Studies of chronic atrial fibrillation have shown a "protective 
effect" of mitral regurgitation against hromboembolism (38- 
40). Our data demonstrate hat mitral regurgitation, analyzed 
as either a continuous or a dichotomous variable, was not 
significantly different between the groups with and without left 
atrial thrombi. This apparent conflict may reflect differences in
pathophysiology of thrombus formation and thrombus migra- 
tion (embolization), patient population (acute vs. chronic atrial 
fibrillation) or anticoagulation regimens. A recent ransesoph- 
ageal echocardiographic study by Fisher et al. (41) in patients 
with atrial fibrillation also failed to identify mitral regurgitation 
as protective against he formation of left atrial appendage 
thrombi. 
Atrial thrombi were detected in 15% of the patients in the 
present series, a figure similar to that reported by others 
(42,43) but higher than the previously reported incidence of 
emboli from either chronic atrial fibrillation (44) or at cardio- 
version without anticoagulation (6-9). This higher number of 
patients with atrial thrombi most likely approximates the group 
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potentially at risk for early embolization because the number 
of patients who have early embolization will likely be some 
fraction of those with thrombi. Some thrombi may not embo- 
lize and some emboli may be clinically silent. 
Role of anticoagulation in transesophageal echocarflio- 
graphic studies to guide early cardioversion. Recent pub- 
lished reports (45-47) of patients who have experienced 
cardioversion-related mbolic events after transesophageal 
echocardiography ave demonstrated no thrombus before 
cardioversion. However the adverse vents reported (45-47) 
have occurred uniformly in patients who have not received 
therapeutic anticoaguIation with heparin or warfarin before 
transesophageal ehocardiography and extending 3 to 4 weeks 
after cardioversion. Many underwent electrical cardioversion 
several days or weeks after transesophageal chocardiography, 
with no anticoagulation during this interval. For these patients 
it is impossible to exclude the possibility that atrial thrombi 
may have formed either between the transesophageal chocar- 
diography and cardioversion or after cardioversion. Impaired 
atrial mechanical function (16,48) or new spontaneous contrast 
(45,49) has also been well documented after cardioversion. 
The lack of therapeutic anticoagulation in these cases (45-47) 
may have left patients vulnerable during the pericardioversion 
period. As in our preliminary report (22) we continue to 
recommend strongly that all patients admitted to the hospital 
for treatment of atrial fibrillation receive anticoagulation with 
intravenous heparin followed by transesophageal chocardiog- 
raphy only when a therapeutic partial thromboplastin time has 
been achieved. Systemic anticoagulation should then be con- 
tinued for 3 to 4 weeks after cardioversion. Anticoagulation is 
given to minimize the potential for thrombi to develop be~ 
tween the periods of admission, transesophageal chocardio- 
graphic study and cardioversion. Systemic anticoagulation for 3 
to 4 weeks after cardioversion should prevent hrombi from 
forming after cardioversion. To our knowledge this strategy 
has been associated with no thromboembolic events among 
patients undergoing early cardioversion. 
Although 19 patients in our series had uneventful cardio- 
version immediately after transesophageal study and without 
any systemic anticoagulation, the small number of patients 
treated in this manner and the previously, mentioned reports of 
embolic events in patients treated in this manner (45-47) 
preclude our recommendation for cardioversion without anti- 
coagulation. Such a treatment strategy may be reasonable for 
the very small number of subjects in whom even short-term 
intravenous heparin is contraindicated, such as patients with 
active gastrointestinal bleeding or intracranial hemorrhage. A 
transesophageaI chocardiographic approach for such a group 
may be safer than "blind" cardioversion, although this remains 
to be studied. As always the risks and benefits of cardioversion 
for these patients must be considered carefully. 
Clinical implications. Because the previously reported in- 
cidence of cardioversion-associated thromboembolism in pa- 
tients who have received prophylactic anticoagulation (conven- 
tional therapy) is also low, our nonrandomized prospective 
study does not prove that a transesophageal chocardiographi- 
cally guided approach in concert with short-term anticoagula- 
tion is safer than the conventional strategy. A series of >7,000 
randomized patients will be required to compare directly 
transesophageal echocardiographically guided cardioversion 
with prophylactic anticoagulation (22). Such a trial has been 
initiated recently {49), and we support such studies to identify 
which strategy is the safest. Our prospective report of 230 
consecutive patients with atrial fibrillation undergoing cardio- 
version does validate the safety of this approach as equivalent 
to that of conventional therapy and also represents, to our 
knowledge, the largest single prospective study of patients 
undergoing cardioversion with primarily "natural" atrial fibril- 
lation. The absence of any embolic events in our series argues 
favorably for this approach to cardioversion for hospitalized 
patients with atrial fibrillation. Recent data also have sug- 
gested that this approach is cost-effective in this population 
{50). 
We do not advocate the use of transesophageal chocardi- 
ography in all patients with atrial fibrillation. Our study 
included patients hospitalized for treatment of atrial fibrilla- 
tion. The role and especially the cost-effectiveness of trans- 
esophageal echocardiography in the treatment of outpatients 
with atrial fibrillation and its role in patients with atrial flutter, 
remain to be determined. We did not study patients with 
postoperative atrial fibrillation because they were recognized 
early (<2 days), thus excluding them from this study. We also 
do not support he routine use of transesophageal chocardi- 
ography before cardioversion i patients who have had ade- 
quate anticoagulation with prolonged (>3 weeks) warfarin 
therapy before planned cardioversion. It does seem reasonable 
to consider transesophageal echocardiographic study (even 
after 3 weeks of warfarin) for those patients in whom the initial 
presentation i cluded acute thromboembolism or for those in 
whom warfarin anticoagulation has been intermittently sub- 
therapeutic, but these groups remain to be studied. 
Study limitations. Our study was not designed to compare 
the sensitivity or specificity of different ransesophageal cho- 
cardiographic imaging planes for the detection of atrial 
thrombi. The superiority of biplane examination for imaging 
both atria and appendages has been reported by several 
observers (51,52), and our data corroborate those reports. The 
additional value of multiplane transesophageal chocardiogra- 
phy in this setting remains to be defined, although we currently 
perform only multiplane xaminations. We devote consider- 
able time during the transesophageal chocardiographic exam- 
ination to studying the atria/appendage. Using this strategy the 
accuracy of transesophageal echocardiography in identifying 
atrial thrombi s extremely high (17,18,53), although certainly 
there is a finite resolution to transesophageal chocardiogra- 
phy and very small thrombi may be missed. It is for this reason 
that we strongly recommend systemic heparin at the time of 
transesophageal study, extending for 3 to 4 weeks after suc- 
cessful cardioversion. Treatment of patients in whom the atrial 
appendage is not adequately visualized by transesophageal 
cchocardiography would be best accomplished with conserva- 
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tive therapy with prolonged warfarin before (and after) 
cardioversion. 
Conclusions. This large prospective and consecutive study 
documents the safety of transesophageal echocardiography in
concert with short-term anticoagulation to facilitate early 
cardioversion for hospitalized patients with atrial fibrillation of 
unknown or prolonged duration. This approach is as safe as 
conventional therapy. Such a strategy also minimizes the total 
durations of anticoagulation, atrial fibrillation and atrial me- 
chanical dysfunction. 
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